United States · Platforms & data · MarketBeat

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Published by MarketBeat · United States 2 h ago

Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

The Motley Fool

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

MarketWatch

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Share

Also worth reading

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months